About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AMGN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab…
NCT07222553 · Immunoglobulin G4-related Disease
Inebilizumab
AMGN
Amgen
Phase 2Recruiting
was not yet recruiting
15Jun 10, 2031Registry ↗
Nov 13, 2026A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482 · Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Avacopan, Placebo
AMGN
Amgen
Phase 4Recruiting300Dec 31, 2036Registry ↗
Nov 13, 2026A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Com…
NCT05920356 · Non-Small Cell Lung Cancer (NSCLC)
Sotorasib, Pembrolizumab
AMGN
Amgen
Phase 3Recruiting750Jun 30, 2027Registry ↗
Nov 12, 2026A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibe…
NCT07614776 · Neovascular Age-related Macular Degeneration, nAMD
ABP 938 8 mg, Aflibercept (US) 8 mg
AMGN
Amgen
Phase 3Recruiting304Jul 31, 2027Registry ↗
Nov 12, 2026Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen…
NCT07140900 · Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Xaluritamig, Darolutamide
AMGN
Amgen
Phase 1Active, not recruiting
was recruiting
60Oct 27, 2027Registry ↗
Nov 12, 2026Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542 · Prostate Cancer
AMG 509, Abiraterone
AMGN
Amgen
Phase 1Recruiting505Jul 28, 2030Registry ↗
Nov 10, 2026A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
NCT07745907 · Healthy Participants
AMG 691
AMGN
Amgen
Phase 1Active, not recruiting
was recruiting
28Mar 17, 2027Registry ↗
Nov 10, 2026Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
NCT03792841 · Metastatic Castration-resistant Prostate Cancer, Prostate C…
acapatamab, Pembrolizumab
AMGN
Amgen
Phase 1Terminated212Jun 29, 2023Registry ↗
Nov 9, 2026Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity…
NCT07871409 · Obesity, Overweight
Maridebart cafraglutide, Autoinjector
AMGN
Amgen
Phase 3Recruiting
was not yet recruiting
230Jun 16, 2027Registry ↗
Nov 9, 2026EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747 · Cardiovascular Disease, Myocardial Infarction
Evolocumab, Routine Lipid Management
AMGN
Amgen
Phase 4Active, not recruiting6,019May 29, 2027Registry ↗
Nov 6, 2026Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When…
NCT07921316 · Obesity, Overweight
Maridebart cafraglutide
AMGN
Amgen
Phase 1Not yet recruiting356Jul 26, 2027Registry ↗
Nov 6, 2026Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-…
NCT07575399 · Obesity or Overweight
Maridebart Cafraglutide
AMGN
Amgen
Phase 3Recruiting300Jan 3, 2028Registry ↗
Nov 6, 2026Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Sma…
NCT06211036 · Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Can…
Tarlatamab, Durvalumab
AMGN
Amgen
Phase 3Active, not recruiting563Apr 2, 2030Registry ↗
Nov 5, 2026Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
NCT07866066 · Diabetes Mellitus, Type 2
Maridebart cafraglutide, Semaglutide
AMGN
Amgen
Phase 3Recruiting
was not yet recruiting
1,300Sep 6, 2028Registry ↗
Nov 4, 2026A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Pso…
NCT05767047 · Behçet's Disease, Juvenile Psoriatic Arthritis
Apremilast
AMGN
Amgen
Phase 3Recruiting48Mar 17, 2036Registry ↗
Nov 4, 2026Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small…
NCT03319940 · Small Cell Lung Carcinoma
Tarlatamab, Pembrolizumab
AMGN
Amgen
Phase 1Active, not recruiting269Dec 31, 2027Registry ↗
Nov 3, 2026A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
NCT07598825 · Autoimmune Hepatitis, AIH
Inebilizumab, Placebo
AMGN
Amgen
Phase 3Recruiting180Jul 30, 2031Registry ↗
Nov 2, 2026Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an E…
NCT07908641 · Psoriasis, Arthritis, Psoriatic
Apremilast XR, Apremilast IR
AMGN
Amgen
Phase 1Not yet recruiting114Jan 10, 2027Registry ↗
Nov 2, 2026Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants…
NCT07908316 · Obesity, Overweight
Maridebart cafraglutide
AMGN
Amgen
Phase 1Recruiting180Dec 20, 2027Registry ↗
Nov 2, 2026Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B P…
NCT06054113 · B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refracto…
Blinatumomab
AMGN
Amgen
Phase 2Active, not recruiting18Jan 6, 2026Registry ↗
Oct 30, 2026A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Partici…
NCT06637371 · Asthma
AMG 691, Placebo
AMGN
Amgen
Phase 1Active, not recruiting21Apr 10, 2027Registry ↗
Oct 29, 2026Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sar…
NCT07297979 · Ewing Sarcoma
Xaluritamig
AMGN
Amgen
Phase 1Recruiting50May 26, 2030Registry ↗
Oct 29, 2026Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obe…
NCT07037459 · Heart Failure With Preserved Ejection Fraction, Heart Failu…
Maridebart cafraglutide, Placebo
AMGN
Amgen
Phase 3Recruiting5,056Jun 30, 2028Registry ↗
Oct 29, 2026Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With At…
NCT07037433 · Atherosclerotic Cardiovascular Disease, Overweight
Maridebart Cafraglutide, Placebo
AMGN
Amgen
Phase 3Active, not recruiting
was recruiting
12,800Jun 30, 2028Registry ↗
Oct 29, 2026A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome…
NCT06104124 · Sjogren's Syndrome
Dazodalibep, Placebo
AMGN
Amgen
Phase 3Completed651Jul 23, 2026Registry ↗
Oct 29, 2026Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to…
NCT05909761 · Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
UPLIZNA
AMGN
Amgen
—Recruiting60Oct 31, 2032Registry ↗
Oct 28, 2026A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants…
NCT05481411 · Hepatic Impairment
Olpasiran
AMGN
Amgen
Phase 1Completed25Apr 5, 2023Registry ↗
Oct 28, 2026Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
NCT03832998 · Migraine
Erenumab Dose 1, Erenumab Dose 2
AMGN
Amgen
Phase 3Completed284Jan 8, 2025Registry ↗
Oct 27, 2026Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303 · Atherosclerotic Cardiovascular Disease
Placebo, Olpasiran
AMGN
Amgen
Phase 3Active, not recruiting7,297Mar 31, 2028Registry ↗
Oct 23, 2026A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab…
NCT06987539 · Generalized Myasthenia Gravis
Inebilizumab
AMGN
Amgen
Phase 2Recruiting15Mar 13, 2030Registry ↗
Oct 23, 2026A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
NCT06411860 · Basic Science
Placebo, Olpasiran
AMGN
Amgen
Phase 1Completed32Nov 29, 2024Registry ↗
Oct 23, 2026A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy P…
NCT06268860 · Atopic Dermatitis
Rocatinlimab vial injection, Rocatinlimab prefilled syringe
AMGN
Amgen
Phase 1Completed240Aug 30, 2024Registry ↗
Oct 23, 2026A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199 · Plaque Psoriasis
Apremilast
AMGN
Amgen
Phase 3Completed51Aug 12, 2026Registry ↗
Oct 23, 2026A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants…
NCT05489614 · Renal Impairment
Olpasiran
AMGN
Amgen
Phase 1Completed33Oct 24, 2023Registry ↗
Oct 23, 2026Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Recepto…
NCT05052801 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab, mFOLFOX6
AMGN
Amgen
Phase 3Completed547Jun 20, 2025Registry ↗
Oct 23, 2026Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
NCT04362748 · Advanced Solid Tumors
AMG 256
AMGN
Amgen
Phase 1Completed34Sep 21, 2023Registry ↗
Oct 23, 2026Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointesti…
NCT03362177 · Chemotherapy-induced Thrombocytopenia
Romiplostim, Placebo
AMGN
Amgen
Phase 3Completed165Jan 25, 2024Registry ↗
Oct 21, 2026Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two…
NCT06502977 · Extensive Stage Small Cell Lung Cancer
Tarlatamab
AMGN
Amgen
Phase 2Active, not recruiting32Mar 28, 2025Registry ↗
Oct 21, 2026A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk…
NCT06079476 · Postmenopausal Osteoporosis
Romosozumab
AMGN
Amgen
Phase 4Completed100Oct 18, 2025Registry ↗
Oct 20, 2026AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721 · Metastatic or Locally Advanced Solid Tumors With Microsatel…
AMG 436
AMGN
Amgen
Phase 1Recruiting464Jan 1, 2030Registry ↗
Oct 20, 2026A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemother…
NCT07213674 · Metastatic Castration-resistant Prostate Cancer
Xaluritamig, Abiraterone acetate
AMGN
Amgen
Phase 3Recruiting750Jan 7, 2030Registry ↗
Oct 20, 2026Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553 · Active Juvenile Psoriatic Arthritis
Apremilast, Placebo
AMGN
Amgen
Phase 3Recruiting60Mar 21, 2028Registry ↗
Oct 19, 2026A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokineti…
NCT07388498 · Uncontrolled Gout
Pegloticase, Methotrexate
AMGN
Amgen
Phase 3Recruiting270Jun 18, 2028Registry ↗
Oct 19, 2026Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advance…
NCT05800964 · Advanced Solid Tumors
AMG 305
AMGN
Amgen
Phase 1Terminated37Jan 22, 2026Registry ↗
Oct 19, 2026Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cel…
NCT03937154 · Chemotherapy-induced Thrombocytopenia
Romiplostim, Placebo
AMGN
Amgen
Phase 3Active, not recruiting145Mar 10, 2026Registry ↗
Oct 14, 2026Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040 · Migraine
Erenumab Dose 1, Erenumab Dose 2
AMGN
Amgen
Phase 3Active, not recruiting457Nov 19, 2025Registry ↗
Oct 13, 2026Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered…
NCT07811999 · Healthy Participants
Romosozumab
AMGN
Amgen
Phase 1Recruiting308Jan 14, 2027Registry ↗
Oct 13, 2026A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living W…
NCT07310563 · Overweight, Obesity
AMG 133, Ondansetron
AMGN
Amgen
Phase 1Completed59May 9, 2025Registry ↗
Oct 6, 2026Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positi…
NCT07225686 · Obesity, Obstructive Sleep Apnea
Maridebart cafraglutide, Placebo
AMGN
Amgen
Phase 3Active, not recruiting250Aug 20, 2027Registry ↗
Oct 6, 2026A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With…
NCT06745323 · Small Cell Lung Cancer (SCLC)
Tarlatamab
AMGN
Amgen
Phase 2Active, not recruiting252Aug 10, 2029Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:57 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances